InfraReDx Announces Publication Of Prospective Study Demonstrating That Near-Infrared Spectroscopy May Assist In Predicting The Risk Of Future Cardiovascular Events, Including Heart Attack And Stroke

BURLINGTON, Mass.--(BUSINESS WIRE)--Infraredx, Inc., a cardiovascular imaging company pioneering the personalized diagnosis of coronary artery disease, today announced results from an independent, prospective outcomes study published in the Journal of the American College of Cardiology (JACC). The study evaluated the ability of intravascular near-infrared spectroscopy (NIRS) to identify lipid core-containing plaques, which are believed to be implicated in most heart attacks, as a means to predict the risk of future major adverse cardiac and cerebrovascular events (MACCE). In the study, patients who presented with symptoms associated with limited blood supply to the heart also underwent NIRS imaging to evaluate the Lipid Core Burden Index (LCBI) in an artery that was not directly implicated in causing their symptoms. The results, which were published online on Dec. 8 and will appear in the Dec. 16 print edition of JACC, demonstrated that patients with an LCBI = 43 in a non-culprit artery had a fourfold risk of MACCE, such as heart attack or stroke, within the following year. In addition, the study concluded that non-culprit vessel LCBI reflects vascular vulnerability of the larger coronary tree.

Help employers find you! Check out all the jobs and post your resume.